Dianthus Therapeutics Inc. (DNTH) - Total Assets
Based on the latest financial reports, Dianthus Therapeutics Inc. (DNTH) holds total assets worth $1.21 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Dianthus Therapeutics Inc. - Total Assets Trend (2016–2025)
This chart illustrates how Dianthus Therapeutics Inc.'s total assets have evolved over time, based on quarterly financial data. Also see market value of Dianthus Therapeutics Inc. for the company's overall valuation and market capitalisation.
Dianthus Therapeutics Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Dianthus Therapeutics Inc.'s total assets of $1.21 Billion consist of 77.1% current assets and 22.9% non-current assets. Review DNTH liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.6% |
| Accounts Receivable | $102.00K | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Dianthus Therapeutics Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Dianthus Therapeutics Inc. for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Dianthus Therapeutics Inc.'s current assets represent 77.1% of total assets in 2025, a decrease from 95.5% in 2016.
- Cash Position: Cash and equivalents constituted 9.6% of total assets in 2025, down from 40.1% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 0.0% of total assets.
Dianthus Therapeutics Inc. Competitors by Total Assets
Key competitors of Dianthus Therapeutics Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Dianthus Therapeutics Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 26.10 | 13.12 | 19.36 |
| Quick Ratio | 26.10 | 13.12 | 19.36 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $863.15 Million | $243.51 Million | $186.33 Million |
Dianthus Therapeutics Inc. - Advanced Valuation Insights
This section examines the relationship between Dianthus Therapeutics Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.21 |
| Latest Market Cap to Assets Ratio | 11.04 |
| Asset Growth Rate (YoY) | 42.0% |
| Total Assets | $530.92 Million |
| Market Capitalization | $5.86 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Dianthus Therapeutics Inc.'s assets at a significant premium (11.04x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Dianthus Therapeutics Inc.'s assets grew by 42.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Dianthus Therapeutics Inc. (2016–2025)
The table below shows the annual total assets of Dianthus Therapeutics Inc. from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $530.92 Million | +41.95% |
| 2024-12-31 | $374.01 Million | +108.47% |
| 2023-12-31 | $179.41 Million | +115.86% |
| 2022-12-31 | $83.11 Million | -56.24% |
| 2021-12-31 | $189.93 Million | +17.52% |
| 2020-12-31 | $161.62 Million | +0.07% |
| 2019-12-31 | $161.51 Million | +2.67% |
| 2018-12-31 | $157.31 Million | +188.84% |
| 2017-12-31 | $54.46 Million | +380.19% |
| 2016-12-31 | $11.34 Million | -- |
About Dianthus Therapeutics Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that target… Read more